2-((3R,5R,6S)-1-((S)-1-(tert-butoxy)-1-oxo-butan-2-yl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-2-oxopiperidin-3-yl)acetic acid | 1352062-52-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 2-((3R,5R,6S)-1-((S)-1-(tert-butoxy)-1-oxo-butan-2-yl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-2-oxopiperidin-3-yl)acetic acid
• 英文别名: [(3r,5r,6s)-1-[(2s)-1-Tert-Butoxy-1-Oxobutan-2-Yl]-5-(3-Chlorophenyl)-6-(4-Chlorophenyl)-2-Oxopiperidin-3-Yl]acetic Acid；2-[(3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-[(2S)-1-[(2-methylpropan-2-yl)oxy]-1-oxobutan-2-yl]-2-oxopiperidin-3-yl]acetic acid
• CAS: 1352062-52-2
• 化学式: C₂₇H₃₁Cl₂NO₅
• 分子量: 520.453
• InChiKey: ZEMLYWMOSZRCQL-UWSZBUKDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  35
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  83.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-((3R,5R,6S)-1-((S)-1-(tert-butoxy)-1-oxo-butan-2-yl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-2-oxopiperidin-3-yl)acetic acid 在 N-甲基吗啉 、 氨 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 1.5h， 生成 (S)-tert-butyl 2-((3R,5R,6S)-3-(2-amino-2-oxo-ethyl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-2-oxopiperidin-1-yl)-butanoate
  参考文献：
  名称：

  Structure-Based Design of Novel Inhibitors of the MDM2–p53 Interaction

  摘要：

  Structure-based rational design led to the discovery of novel inhibitors of the MDM2-p53 protein-protein interaction. The affinity of these compounds for MDM2 was improved through conformational control of both the piperidinone ring and the appended N-alkyl substituent. Optimization afforded 29 (AM-8553), a potent and selective MDM2 inhibitor with excellent pharmacokinetic properties and in vivo efficacy.

  DOI：

  10.1021/jm300354j
• 作为产物：
  描述：

  3-氯苯乙酸 在 甲醇 、 sodium tetrahydroborate 、 sodium periodate 、 sodium azide 、 ruthenium(III) trichloride hydrate 、 potassium tert-butylate 、 sodium hexamethyldisilazane 、 sodium hydride 、 碳酸氢钠 、 三乙胺 、 lithium hexamethyldisilazane 、 三甲基膦 作用下， 以 四氢呋喃 、 甲醇 、 四氯化碳 、 正己烷 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 异丙醇 、 乙腈 、 mineral oil 为溶剂， 反应 37.41h， 生成 2-((3R,5R,6S)-1-((S)-1-(tert-butoxy)-1-oxo-butan-2-yl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-2-oxopiperidin-3-yl)acetic acid
  参考文献：
  名称：

  Structure-Based Design of Novel Inhibitors of the MDM2–p53 Interaction

  摘要：

  Structure-based rational design led to the discovery of novel inhibitors of the MDM2-p53 protein-protein interaction. The affinity of these compounds for MDM2 was improved through conformational control of both the piperidinone ring and the appended N-alkyl substituent. Optimization afforded 29 (AM-8553), a potent and selective MDM2 inhibitor with excellent pharmacokinetic properties and in vivo efficacy.

  DOI：

  10.1021/jm300354j

文献信息

• [EN] PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE LA PIPÉRIDINONE EN TANT QU'INHIBITEURS DE MDM2 POUR LE TRAITEMENT DU CANCER
  申请人：AMGEN INC

  公开号：WO2011153509A1

  公开（公告）日：2011-12-08

  The present invention provides MDM2 inhibitor compounds of Formula (I), wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

  本发明提供了式（I）的MDM2抑制剂化合物，其中变量如上所定义，这些化合物可用作治疗剂，特别是用于癌症的治疗。本发明还涉及含有MDM2抑制剂的药物组合物。
• PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：BARTBERGER Michael David

  公开号：US20110319378A1

  公开（公告）日：2011-12-29

  The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

  本发明提供了公式I的MDM2抑制剂化合物，其中变量如上所定义，这些化合物可用作治疗剂，特别是用于治疗癌症。本发明还涉及含有MDM2抑制剂的药物组合物。
• Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer
  申请人：Gribble, Jr. Michael

  公开号：US08569341B2

  公开（公告）日：2013-10-29

  The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

  本发明提供了式I的MDM2抑制剂化合物，其中变量如上所定义，该化合物可用作治疗剂，特别是用于治疗癌症。本发明还涉及含有MDM2抑制剂的药物组合物。
• Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer
  申请人：AMGEN INC.

  公开号：US20160137667A1

  公开（公告）日：2016-05-19

  The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

  本发明提供了式I的MDM2抑制剂化合物，其中变量如上所定义，该化合物可用作治疗剂，特别是用于治疗癌症。本发明还涉及含有MDM2抑制剂的制药组合物。
• US8569341B2
  申请人：——

  公开号：US8569341B2

  公开（公告）日：2013-10-29